At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
CD14152 Dose A +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN)
In Brief
A Phase 2 clinical trial evaluating CD14152 Dose A and CD14152 placebo for Prurigo Nodularis. Completed, enrolled 70 participants across 16 sites in 4 countries.
Detailed Summary
The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrurigo Nodularis
CountriesAustria, France, Germany, Poland
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartOct 2017
Primary CompletionSep 2018
TodayJul 2026
First PostedJun 8, 2017
Enrollment StartOct 2, 2017
Primary CompletionSep 26, 2018
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 9.1 years ago
Interventions
CD14152 Dose Adrug
3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
CD14152 placebodrug
3 subcutaneous injections (every 4 weeks during the 12-week treatment period)